Please login to the form below
16
Revenue 2017Shire
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shire's 2013 CNS, immunology and metabolic's sales performance.
Testimonials
With the integration of Shire into our UK &Ireland team we will continue to empower our people to be ambitious and change the game for patients, a key achievement of our
Antony Faupel
He has significant UK experience with GlaxoSmithKline and MSD in most therapeutic areas and, also, in specialist and rare diseases with Takeda Europe and Shire Global.
Sourcing R&D innovation: why pharma companies need to evolve their business models
including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.
Pfizer doses first patient in investigational haemophilia drug trial
A number of treatments on the market are designed to replace factor VII, including both short-acting and newer long-acting versions such as Shire’s Adynovate, Biogen’s Eloctate,
Takeda to sell Japan consumer health unit for $2.3bn
Last year, Takeda acquired Irish biotech company Shire for £46bn, which gave the Japanese pharma company access to a solid platform of rare diseases. ... As well as completing $10bn in divestment transactions, Takeda has made other sacrifices for the
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- MIT researchers develop AI model to detect future lung cancer risk
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Fishawack Health welcomes Mario Muredda as its new President of Marketing
- Pharmaceutical Marketing Strategies For The Digital Age
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Roche’s Polivy recommended by NICE for lymphoma therapy
- A bundle of nerves
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
- The challenges of identifying rare diseases
- With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
